左卡尼汀重组人促红细胞生长素及铁剂联合治疗血液透析患者的疗效及并发症发生情况分析

doi:10.3969/j.issn.1006-6233.2018.11.026

Abstract
Figure/Table
References
Related Citation (14)

Download: PDF (1252 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effects of combined treatment with L-carnitine, recombinant human erythropoietin and iron on the clinical efficacy and complications of hemodialysis patients. Methods: 92 hemodialysis patients who were admitted to our hospital from May 2017 to May 2018 were selected and randomly divided into control group (n=46) and observation group (n=46) according to the random number table method; Recombinant human erythropoietin and iron were only given. Patients in the observation group were treated with levocarnitine, recombinant human erythropoietin, and iron; clinical efficacy was compared between the two groups. Results: After treatment, the incidence of complications in the observation group and the control group were 2.17% (1/46) and 15.22% (7/46), respectively. The difference between the two groups was statistically significant (χ²= 4.929, P<0.05). Before treatment, there was no significant difference in iron transgenic protein saturation, hematocrit, serum ferritin and hemoglobin between the two groups (P>0.05). The levels of the indicators in the observation group were compared with the control group. The differences between the two groups after treatment were compared, and the differences in improvement were not compared. There were significant differences between the two groups (t=7.107, 12.581, 38.529, 12.024; P<0.05); The levels of blood urea nitrogen, blood urea and serum creatinine were significantly lower in the patients after treatment than in the control group (t=8.855, 18.612, 37.383; P<0.05). Conclusion: The combination of levocarnitine, recombinant human erythropoietin, and iron in patients with hemodialysis complications can effectively improve the clinical symptoms of patients and promote the improvement of renal function. The incidence of adverse reactions is low, and the safety is high. Clinical promotion.

Key words： Hemodialysis L-carnitine Recombinant human erythropoietin Iron

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.11.026 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I11/1867

[1] 杨世霞,徐进,李建省,等.左卡尼汀联合重组人促红细胞生长素及铁剂治疗血液透析并发症的疗效观察[J].中国临床药理学杂志.2013,29(4):254~256.
[2] 李新华,杨红荣,刘丹,等.左卡尼汀、重组人促红细胞生长素及铁剂联合治疗血液透析并发症的临床效果[J].华南国防医学杂志.2014,28(1):25~27.
[3] 金海姣,方炜,朱铭力,等.终末期肾病患者不同紧急透析方式的并发症及预后比较[J].中华肾脏病杂志.2016,32(10):739~744.
[4] Ahmadi Sedigheh,Dehghan Banadaki Shima,Mozaffari-Khosravi Hassan.Effects of oral L-carnitine supplementation on leptin and adiponectin levels and body weight of hemodialysis patients:a randomized clinical trial.[J].Iranian journal of kidney diseases,2016,10(3)144~150.
[5] 任红旗.血液透析患者动静脉内瘘与心血管系统并发症[J].肾脏病与透析肾移植杂志.2016,25(6):563~567.
[6] Kei Fukami,Sho-ichi Yamagishi,Kazuko Sakai,et al.Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients[J].Journal of Cardiovascular Pharmacology,2015,65(3)289~295.
[7] 李晓萌,陈玉珍,白玉梅,等.维持性血液透析患者自体动静脉内瘘血管并发症的超声观察[J].中国中西医结合肾病杂志.2017,18(8):726~727.
[8] 尤啸澜,范佳妮.维持性血液透析合并贫血患者治疗后达标情况及其影响因素分析[J].中国血液净化.2017,16(8):519~521.
[9] 占雅萍,戴慧莉,张伟明,等.内皮祖细胞与维持性血液透析患者心血管并发症的关系[J].中华肾脏病杂志.2016,32(12):881~887.
[10] 林燕娜,冯志瑀,黎志彬,等.慢性肾衰竭维持性血液透析合并不宁腿综合征的中医证候研究[J].广州中医药大学学报.2018,35(3):383~387.
[11] 潘月娟,卢方平.大剂量左卡尼汀在不能耐受血液透析的尿毒症合并心脏病患者中的应用[J].中华医学杂志.2017,97(48):3792~3795.